tiziana-logo.png
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
July 21, 2023 16:15 ET | Tiziana Life Sciences Ltd.
NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel...
tiziana-logo.png
Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
June 13, 2023 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
tiziana-logo.png
Tiziana Life Sciences meldet Verringerung der mikroglialen Aktivierung bei insgesamt 5 von 6 an nicht-aktiver sekundär progredienter Multipler Sklerose erkrankten Patienten mit erweitertem Zugang zu intranasalem Foralumab
June 06, 2023 09:03 ET | Tiziana Life Sciences Plc
Die Ergebnisse bestätigen das positive Signal, das zuvor bei den ersten beiden Patienten mit erweitertem Zugang berichtet wurde, die beide anschließend klinische Verbesserungen zeigtenPhase-IIa-Studie...
Figure 1
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
June 05, 2023 10:00 ET | Tiziana Life Sciences Ltd.
Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvementsPhase 2a trial in na-SPMS on track to begin in Q3...
tiziana-logo.png
Tiziana Life Sciences veranstaltet KOL-Webinar zu Foralumab bei nicht-aktiver sekundär-progredienter Multipler Sklerose (SPMS)
May 26, 2023 05:21 ET | Tiziana Life Sciences Plc
NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) („Tiziana“ oder das „Unternehmen“), ein Biotechnologieunternehmen, das bahnbrechende Immunmodulationstherapien...
tiziana-logo.png
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
May 25, 2023 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
tiziana-logo.png
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
May 23, 2023 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
tiziana-logo.png
Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17
May 17, 2023 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, May 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
tiziana-logo.png
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
April 27, 2023 07:00 ET | Tiziana Life Sciences Ltd.
There are no effective treatments for intracerebral hemorrhage (ICH), which has a 30% to 40% mortality rateIntranasal anti-CD3 mAb treatment showed a reduction in Intracerebral Hemorrhage injury...
tiziana-logo.png
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update
April 26, 2023 14:47 ET | Tiziana Life Sciences Ltd.
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...